Coherus And Superior Biologics Announce National Distribution Agreement For YUSIMRY; At A Price Of $995 Per Carton Of Two Autoinjectors, A Discount Of More Than 85% Compared To Humira, Currently Priced At $6,922 Per Carton Of Two Pens
Portfolio Pulse from Happy Mohamed
Coherus BioSciences, Inc. (NASDAQ:CHRS) and Superior Biologics, Inc. have announced a national distribution agreement for YUSIMRY, a biosimilar of Humira, at a price of $995 per carton of two autoinjectors, representing a discount of more than 85% compared to Humira. This is the first formal distribution agreement for YUSIMRY and is expected to provide patients and employers with a low-cost, high-quality treatment option.
July 13, 2023 | 12:44 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The distribution agreement for YUSIMRY could potentially increase the market share and revenues of Coherus BioSciences, given the significant price discount compared to Humira. This could have a positive impact on the company's stock price in the short term.
The distribution agreement for YUSIMRY, a biosimilar of Humira, at a significant price discount could potentially attract a large number of patients and employers looking for a low-cost, high-quality treatment option. This could increase the market share and revenues of Coherus BioSciences, which could have a positive impact on the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100